Today, International Stem Cell Corp.,
a California-based biotech developing novel stem cell-based therapies and
biomedical products, updated investors with latest happenings and reported its
fourth quarter and year-end financial results for the period ended December 31,
2014.
Q4 highlights:
• The
Court of Justice of the European Union ruled in favor of the Company’s EU
patent applications, opening the way to the issuance of ISCO’s core technology
patents in the EU in 2015 and significantly strengthening the Company’s
intellectual property estate
• Received
clearance from the U.S. Food and Drug Administration, in an important ruling,
for ISCO’s human parthenogenetic stem cell line for investigational clinical
use; the FDA accepted the use of parthenogenetic stem cells as a starting
material for the development of human cellular therapeutics
• Presented
results from preclinical studies of ISC-hpNSC, ISCO’s human parthenogenetic
neural stem cell clinical product, including long-term safety data and
proof-of-concept efficacy data in Parkinson’s disease, at Neuroscience, the
annual meeting of the Society for Neuroscience in Washington D.C.
• Awarded
the designation of one of America’s fastest growing companies as highlighted in
Deloitte’s 2014 Technology Fast 500™ list in recognition of ISCO’s rate of
growth in sales over the last several years.
Also notable, in January of this
year, the company announced the completion of the required preclinical studies
and plans to begin a phase 1/2a clinical study of its ISC-hpNSC cell therapy in
Parkinson’s disease in Australia. As part of this expansion, ISCO has formed an
Australian subsidiary, Cyto Therapeutics Pty Ltd.
FY 2014 Financial highlights:
• $7.02
million in revenue for the year ended December 31, 2014, an increase of 14%
compared to 2013; Lifeline Skin Care sales up 9% and Lifeline Cell Technology
sales up 19%. Gross margin stable at 73%
• Operating
income from Lifeline Skin Care and Lifeline Cell Technology subsidiaries up 55%
to $1.02 million for the year ended December 31, 2014, compared with $0.65
million in 2013.
• Average
net cash used in operating activities of $0.54 million per month for the year
ending December 31, 2014; The company ended 2014 with cash of $1.11 million
“We delivered on some very important
milestones in the last three months of 2014, including bringing to a successful
conclusion our patent applications with the CJEU and obtaining clearance for
the clinical use of our stem cell lines from the U.S. FDA,” stated Andrey
Semechkin, Ph.D., CEO and Co-chairman of ISCO. “These achievements add further
momentum to both our Parkinson’s program and our business development plans. We
expect to make more progress in 2015, including starting our clinical trial in
Parkinson’s disease patents and to potentially report interim data before the
end of 2015.”
Simon Craw PhD, Executive Vice
President, Jay Novak, Chief Financial Officer and Ruslan Semechkin PhD, Chief
Scientific Officer, of International Stem Cell will host the conference call
scheduled for tomorrow. To attend the call, please use the dial in information
below:
Conference call and webcast details
Date: Wednesday April 1, 2015
Time: 11:00 a.m. ET
Toll-free (US only): 1-888-329-8877
Toll/International: 1-719-457-2648
Conference ID: 1112311
Webcast:
http://public.viavid.com/index.php?id=113470
Please log in at least 10-minutes
before the call start time to ensure timely participation.
A playback of the call will be
available from 4/1/15 at 2:00 pm Eastern Time to 4/15/15 at 11:59 pm Eastern
Time.
Teleconference Replay Details:
Toll free: 1-877-870-5176
Toll/International: 1-858-384-5517
Replay Pin Number: 1112311
For more information on International
Stem Cell Corp., visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment